Elicio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Elicio Therapeutics, Inc. (ELTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 546.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 21.21K shares, a 92.08% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 524.79K shares, a 38.70% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 165.09K shares, a 377.15% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 9.80K shares, a 96.65% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 821.19K shares, a 2.79% increase from fiscal 2024.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 798.93K shares, a 263.69% increase from fiscal 2023.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 219.67K shares, a 90.27% decline from fiscal 2022.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.26M shares, a 104.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 21.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 546.00K shares 10-Q · filed 2026-08-13 | 711.10K shares derived: sum of 3 quarters · filed 2026-08-13 | 720.90K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 524.79K shares 10-Q · filed 2026-05-11 | 689.89K shares derived: sum of 2 quarters · filed 2026-05-11 | 699.69K shares derived: sum of 3 quarters · filed 2026-05-11 | 967.61K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 165.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 174.89K shares derived: sum of 2 quarters · filed 2026-03-12 | 442.82K shares derived: sum of 3 quarters · filed 2026-03-12 | 821.19K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 9.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 277.72K shares derived: sum of 2 quarters · filed 2025-11-13 | 656.10K shares 10-Q · filed 2025-11-13 | 690.70K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 267.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 646.30K shares 10-Q · filed 2025-08-07 | 680.90K shares derived: sum of 3 quarters · filed 2025-08-07 | 973.30K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 378.38K shares 10-Q · filed 2025-05-13 | 412.98K shares derived: sum of 2 quarters · filed 2025-05-13 | 705.38K shares derived: sum of 3 quarters · filed 2025-05-13 | 714.98K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 34.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 327.00K shares derived: sum of 2 quarters · filed 2025-03-31 | 336.60K shares derived: sum of 3 quarters · filed 2025-03-31 | 798.93K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 292.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 302.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 764.33K shares 10-Q · filed 2024-11-13 | 797.43K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 9.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 471.93K shares 10-Q · filed 2024-08-13 | 505.03K shares derived: sum of 3 quarters · filed 2024-08-13 | 556.08K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 462.33K shares 10-Q · filed 2024-05-15 | 495.43K shares derived: sum of 2 quarters · filed 2024-05-15 | 546.48K shares derived: sum of 3 quarters · filed 2024-05-15 | 682.01K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 33.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 84.15K shares derived: sum of 2 quarters · filed 2024-03-29 | 219.67K shares derived: sum of 3 quarters · filed 2024-03-29 | 219.67K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 51.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 186.57K shares derived: sum of 2 quarters · filed 2023-11-13 | 186.57K shares 10-Q · filed 2023-11-13 | 186.57K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 135.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 135.53K shares 10-Q · filed 2023-08-14 | 135.53K shares derived: sum of 3 quarters · filed 2023-08-14 | 143.93K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | 0.00 shares derived: sum of 2 quarters · filed 2023-05-10 | 8.40K shares derived: sum of 3 quarters · filed 2023-05-10 | 68.40K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 8.40K shares derived: sum of 2 quarters · filed 2023-03-17 | 68.40K shares derived: sum of 3 quarters · filed 2023-03-17 | 2.26M shares 10-K · filed 2023-03-17 |
| 2022-09-30 | 8.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 68.40K shares derived: sum of 2 quarters · filed 2022-11-14 | 2.26M shares 10-Q · filed 2022-11-14 | 2.27M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 2.25M shares 10-Q · filed 2022-08-15 | 2.26M shares derived: sum of 3 quarters · filed 2022-08-15 | 2.33M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 2.19M shares 10-Q · filed 2022-05-16 | 2.20M shares derived: sum of 2 quarters · filed 2022-05-16 | 2.27M shares derived: sum of 3 quarters · filed 2022-05-16 | 2.34M shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 16.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 79.60K shares derived: sum of 2 quarters · filed 2022-03-30 | 147.40K shares derived: sum of 3 quarters · filed 2022-03-30 | 1.10M shares 10-K · filed 2022-03-30 |
| 2021-09-30 | 63.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 131.40K shares derived: sum of 2 quarters · filed 2021-11-12 | 1.09M shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 67.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.02M shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 956.32K shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |